Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC 704865) in Advanced, Poor Prognosis Carcinoid Patients
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2b (Primary) ; Octreotide
- Indications Carcinoid tumour; Carcinoma; Colorectal cancer; Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms S0518
- 02 Jun 2015 Primary endpoint has not been met. (Central-review based progression-free survival), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 27 Feb 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.